NASDAQ: BYSIBeyondspring Inc Stock
$2.11+0.20 (+10.47%)
Updated Apr 22, 2024
BYSI Price
$2.11
Fair Value Price
-$0.46
Market Cap
$82.32M
52 Week Low
$0.65
52 Week High
$4.00
P/E
-2.97x
P/B
-4.55x
P/S
29.67x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.55M
Earnings
-$27.51M
Gross Margin
100%
Operating Margin
-1,783.55%
Profit Margin
-1,774.8%
Debt to Equity
-2.63
Operating Cash Flow
N/A
Beta
0.92
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BYSI Overview
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BYSI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BYSI ($2.11) is overvalued by 562.02% relative to our estimate of its Fair Value price of -$0.46 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BYSI ($2.11) is not significantly undervalued (562.02%) relative to our estimate of its Fair Value price of -$0.46 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BYSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BYSI due diligence checks available for Premium users.
Be the first to know about important BYSI news, forecast changes, insider trades & much more!
BYSI News
Valuation
BYSI fair value
Fair Value of BYSI stock based on Discounted Cash Flow (DCF)
Price
$2.11
Fair Value
-$0.46
Undervalued by
562.02%
BYSI ($2.11) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BYSI ($2.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BYSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BYSI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.97x
Industry
16.21x
Market
41x
BYSI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-4.55x
Industry
5.82x
BYSI's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BYSI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$32.9M
Liabilities
$47.6M
Debt to equity
-2.63
BYSI's short-term assets ($25.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BYSI's long-term liabilities ($40.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BYSI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BYSI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BYSI vs Biotech Stocks
Beyondspring Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.